Dr. Mok Discusses Developing Lung Cancer Treatments

Tony S.K. Mok, BMSc, MD, FRCPC
Published Online: Thursday, September 12, 2013
Tony S.K. Mok, BMSc, MD, FRCPC, professor, Department of Clinical Oncology, Chinese University of Hong Kong, Prince of Wales Hospital Hong Kong, China, discusses how to improve the strategy of developing treatments for lung cancer.

Mok says in order to move forward, multiple parties such as pharmaceutical industries, academic institutions, and the FDA have to make changes.

As an example, Mok says, the FDA should look into how it registers drugs because the current practice of demanding a companion diagnostic may actually be slowing down the development of the drug.

Mok also suggests making changes to the pharmaceutical industry by having external tribunals advise pharmaceutical companies on which drugs to develop rather than wasting money by trying to develop many drugs.

Online CME Activities
Free CME from PER
Advances in Next-Generation Sequencing in Precision Oncology: Solid Tumors
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast Cancer
Newer Options on the Horizon for Non-Small Cell Lung Cancer
PARP Inhibitors: Current and Future Options for Breast and Ovarian Cancer
More Reading
$auto_registration$